Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis (Details)

v3.20.1
Licensing and Other Arrangements - Novartis (Details)
$ / shares in Units, $ in Thousands, € in Millions
 3 Months Ended 12 Months Ended
Aug. 24, 2017
EUR (€)
agreement
item
shares
Aug. 24, 2017
USD ($)
agreement
item
$ / shares
shares
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Licensing and other arrangements            
Revenue from contracts with customers     $ 500 $ 8,026    
Novartis Pharma AG | XOMA-052 License Agreement and I L1 Target License Agreement            
Licensing and other arrangements            
Upfront payment received   $ 25,700        
License agreement consideration received, repayment of debt   14,300        
Common stock premium   $ 200        
Number of license agreements | agreement 2 2        
Number of arrangements | item 1 1        
Number of performance obligations | item 2 2        
Remaining performance obligations   $ 0        
Transaction price   40,200        
Revenue from contracts with customers     0 $ 0 $ 40,200  
Contract assets     0     $ 0
Contract liabilities     0     0
Capitalized contract costs     $ 0     $ 0
Novartis Pharma AG | XOMA-052 License Agreement            
Licensing and other arrangements            
License agreement consideration received   30,000        
Upfront payment received   15,700        
License agreement consideration received, repayment of debt € 12.0 14,300        
Proceeds from issuance of common stock   5,000        
Common stock premium   200        
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   $ 438,000        
Agreement termination prior written notice period 6 months 6 months        
Novartis Pharma AG | XOMA-052 License Agreement | Common Stock            
Licensing and other arrangements            
Issuance of stock, net (in shares) | shares 539,131 539,131        
Purchase price (in dollars per share) | $ / shares   $ 9.2742        
Issuance of common stock, fair value   $ 4,800        
Closing stock price (in dollars per share) | $ / shares   $ 8.93        
Novartis Pharma AG | IL-1 Target License Agreement            
Licensing and other arrangements            
Upfront payment received   $ 10,000